News | August 19, 2025
Novo Nordisk's Wegovy approved in the US for the treatment of MASH
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Reinforcing commitment to ethical and sustainable growth
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
